Illumina, Inc. (FRA:ILU)
Market Cap | 12.74B |
Revenue (ttm) | 4.00B |
Net Income (ttm) | -891.81M |
Shares Out | n/a |
EPS (ttm) | -5.61 |
PE Ratio | n/a |
Forward PE | 21.85 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20 |
Average Volume | 52 |
Open | 78.27 |
Previous Close | 76.90 |
Day's Range | 78.27 - 78.33 |
52-Week Range | 62.29 - 146.32 |
Beta | n/a |
RSI | 63.71 |
Earnings Date | Aug 7, 2025 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial numbers in USD Financial StatementsNews

Dr. Lal PathLabs boots genomics capabilities with Illumina’s NovaSeq™ X Series
Dr. Lal PathLabs Limited (DLPL), one of India’s most trusted names in diagnostics, has taken a major step forward in genomics by adding the advanced NovaSeq™ X Series from Illumina to its dedicated ge...

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push
Illumina will acquire SomaLogic to expand ... Full story available on Benzinga.com
Standard BioTools jumps on sale of SomaLogic to Illumina

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumin...

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling
BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing r...

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) ...

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina ...
Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illum...

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, an...

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn is making bold moves from the lab to the tarmac.
Carl Icahn boosts stakes in CVR Energy, JetBlue, Illumina, among Q1 trades
Illumina stock rises after executives disclose stock purchase

Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage
Live Updates Live Coverage Updates appear automatically as they are published. QSI Earnings Backdrop 11:26 am Quantum-Si operates at the intersection of biotech instrumentation and proteomics, targeti...

Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi...

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, ...

Illumina Analysts Lower Their Forecasts After Q1 Results
Illumina, Inc. (NASDAQ: ILMN) reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday. The company posted quarterly earnings of 97 cents per ...

Illumina Analysts Lower Their Forecasts After Q1 Results
Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac...
Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know
April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ: ILMN), valued between $3,003 and $45,000. According to the April filing, the transaction occurred...